Cost-effectiveness analysis of rifaximin-{alpha} administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France
Conclusion:
For the societal willingness to pay threshold of 27,000 per QALY gained, rifaximin-α in combination with lactulose is a cost-effective and affordable treatment for patients who have experienced at least two prior overt HE episodes.
Source: Therapeutic Advances in Gastroenterology - Category: Gastroenterology Authors: Kabeshova, A., Ben Hariz, S., Tsakeu, E., Benamouzig, R., Launois, R. Tags: Original Research Source Type: research
More News: Clinical Trials | Gastroenterology | Health | Liver | Liver Disease | Neurology | Pathology | Study | Urology & Nephrology | Xifaxan